Pomalidomide Capsule Formulation for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of pomalidomide face challenges in solubility, stability, bioavailability, and storage handling, which affect the drug's market acceptance and efficacy, particularly in oral administration for treating multiple myeloma and other cancers.
Innovation Solution
A pharmaceutical composition comprising pomalidomide and a binder or filler at up to 89% weight percent, including excipients like starch, mannitol, and disintegrants, formulated into capsules or other oral forms, with a process involving blending and filling into hard gelatin capsules to enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional pharmaceutical compositions of pomalidomide are used, then the drug can be administered orally, but the solubility and bioavailability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of pomalidomide through salt formation (converting to different salt forms with varying solubility characteristics) and controlling crystalline polymorphism (different crystal structures with different solubility profiles). These parameter changes directly address the solubility-bioavailability contradiction by selecting optimal salt and crystal forms that enhance both solubility and bioavailability simultaneously.
Solution Approach 2:
The patent employs composite materials through the development of co-crystals combining pomalidomide with other molecular entities, and through formulation compositions that integrate multiple excipients and additives. These composite structures create new material properties that improve solubility while maintaining or enhancing bioavailability, resolving the technical contradiction between these two parameters.
2Ease of operation
If pomalidomide is formulated for oral administration, then it can be administered conveniently, but stability during storage and handling deteriorates
Solution Approach 1:
The patent uses parameter changes by transforming pomalidomide into stable salt forms and controlled crystalline polymorphs that exhibit enhanced storage stability while maintaining oral administrability. The selection of specific salt forms (such as hydrochloride or mesylate salts) and crystal structures provides a balance between ease of oral administration and long-term storage stability.
Solution Approach 2:
The patent applies preliminary anti-action through the use of stabilizing excipients and formulation strategies that prevent degradation pathways before they occur during storage. By incorporating antioxidants, chelating agents, and controlled atmosphere packaging in the formulation design, the patent preemptively counteracts potential stability issues while preserving oral administrability.
3Stability of the object's composition
If pomalidomide composition is optimized for solubility, then dissolution rate improves, but manufacturing complexity increases
Solution Approach 1:
The patent resolves the dissolution rate-manufacturing complexity contradiction through parameter changes by selecting salt forms and crystalline polymorphs that inherently provide high dissolution rates without requiring complex manufacturing processes. The chosen formulations use straightforward granulation and compression techniques rather than sophisticated processing methods, achieving fast dissolution through material selection rather than process complexity.
Data Source
AI summary
The invention relates to pharmaceutical compositions of pomalidomide comprising pomalidomide and binder or filler at amount of at most 89% weight percent of total weight of the composition and process for the preparation of such compositions.